Arrhythmia Management

Evaluation and Diagnosis

• The American College of Cardiology recommends ruling out secondary causes of sinus tachycardia, including hyperthyroidism, anemia, dehydration, fever, infection, pain, anxiety, or emotional stress, medications, stimulants, and underlying cardiac or pulmonary disease 1, 2
• Diagnostic testing should include a 12-lead ECG to confirm sinus tachycardia and exclude other arrhythmias, and 24-hour Holter monitoring to document frequency and duration of tachycardia episodes, heart rate response to activity, and nocturnal normalization of rate 2
• Basic laboratory tests, such as complete blood count, basic metabolic panel, thyroid function tests, and cardiac biomarkers, should be obtained to identify underlying causes of tachycardia 3, 4
• ECG characteristics, including QRS duration, rhythm regularity, P-wave presence and morphology, and relationship between P waves and QRS complexes, are essential for diagnosing tachycardia, according to the American Heart Association 4
• Echocardiography is recommended for all patients with new-onset atrial fibrillation or suspected structural heart disease to evaluate cardiac function, chamber size, and valvular abnormalities 3
• Chest radiograph is recommended if pulmonary disease or heart failure is suspected 3
• Continuous cardiac monitoring is recommended for paroxysmal tachycardias not captured on initial ECG 5
• Transesophageal echocardiography (TEE) is recommended if atrial fibrillation is present and cardioversion is planned 3

Treatment

• Vagal maneuvers, such as Valsalva and carotid sinus massage, are recommended as the first line of treatment for acute termination of tachycardia 2
• Adenosine (6 mg rapid IV push, followed by 12 mg if needed) can be both diagnostic and therapeutic for tachycardia, but should be used with caution in patients with severe coronary artery disease 6, 2
• For hemodynamically unstable patients, the American Heart Association recommends proceeding to immediate synchronized cardioversion 7, 6
• The European Heart Association recommends immediate synchronized cardioversion (Class I recommendation) for unstable patients, with sedation if conscious, maximum output initially, and defibrillator patches positioned at least 8 cm from ICD generator if present 8
• Beta blockers or calcium channel blockers are recommended for long-term management of tachycardia to prevent recurrence, as stated by the American Heart Association 4
• The American College of Cardiology recommends beta blockers as first-line therapy for inappropriate sinus tachycardia, starting with a low dose and titrating as tolerated, with monitoring for side effects including hypotension and fatigue 2, 5
• Non-dihydropyridine calcium channel blockers, such as diltiazem or verapamil, may be considered as second-line therapy if beta blockers are ineffective or not tolerated 2, 5
• Class IC antiarrhythmics, such as flecainide and propafenone, may be used in the absence of structural heart disease, as reported by the American College of Cardiology 2
• IV amiodarone is preferred for impaired LV function in patients with wide-complex tachycardia, as reported by the American College of Cardiology 2
• For polymorphic VT with long QT, the American Heart Association recommends IV magnesium, pacing, or isoproterenol, while for polymorphic VT without long QT, IV amiodarone and beta-blockers are recommended 6

Refractory Cases

• Combination therapy with a beta blocker and ivabradine may be considered for refractory cases, as well as an exercise training program to improve autonomic tone 1
• Sinus node modification by catheter ablation may be considered for severely symptomatic patients unresponsive to medical therapy, with success rates ranging from 66-76% and potential complications including pericarditis, phrenic nerve injury, SVC syndrome, or need for permanent pacing 2, 5
• Catheter ablation may be considered for recurrent episodes of tachycardia, with a 95% success rate and <5% recurrence rate, as stated by the American Heart Association 4
• The European Heart Association recommends catheter ablation (Class I recommendation) for patients with scar-related heart disease and incessant VT or electrical storm, patients with ischemic heart disease and recurrent ICD shocks due to VT, and consideration after first episode of sustained VT in patients with ischemic heart disease and ICD 8
• For electrical storm management (≥3 VT episodes in 24 hours), the European Heart Association recommends urgent catheter ablation (Class I recommendation), deep sedation or general anesthesia, sympathetic blockade (IV beta-blockers), and consideration of neuraxial modulation in refractory cases 8

Prognosis and Treatment Goals

• The risk of tachycardia-induced cardiomyopathy in untreated patients is likely small, and therapy is primarily symptom-driven rather than rate-driven 1, 2, 5
• Caution should be exercised when treating sinus tachycardia, as it may be compensatory in some conditions, such as heart failure or hypovolemia, and "normalizing" the heart rate in these cases could be detrimental 6
• Regular follow-up is recommended to monitor for recurrent arrhythmias, assess ICD function, and optimize medical therapy for underlying heart disease 8
• Risk factor modification, including smoking cessation, blood pressure control, diabetes management, and lipid management, is essential to reduce morbidity and mortality 8
• Monitoring response to treatment and considering 24-hour Holter monitoring if symptoms persist despite therapy is recommended, with referral to an electrophysiologist if symptoms are severe or refractory to medical management, as recommended by the American College of Cardiology 6